MedTrace Logo

Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

NCT00006119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-02-21

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

Conditions

Interventions

DRUG

hydroxyurea

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Didier Frappaz, MD · Centre Leon Berard

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2004-12-31
Completion
2008-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006119 on ClinicalTrials.gov